Brief: Fulcrum Therapeutics Q3 Basic EPS USD -0.31
29/10/2025 11:00
Oct 29 (Reuters) - Fulcrum Therapeutics Q3 operating expenses USD 21.858 million. Q3 operating income USD -21.858 million vs. IBES estimate USD -20.6 million Q3 net income USD -19.595 million
Recent news on Fulcrum Therapeutics
See all newsFulcrum Therapeutics, Inc. expected to post a loss of 14 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
U.S. STOCKS ON THE MOVE - KBR, Vista Energy, Fulcrum Therapeutics
Fulcrum to merge with Slate in all-stock deal after drug setback